It may seem odd to find a review of a diet book on a web site devoted to cancer, but there are good reasons for looking at this book. Firstly, it's an accepted fact that there is a strong link between obesity, metabolism and cancer. Secondly, there is an increasing view among some researchers that cancer is a metabolic syndrome, and that cancers are associated with a whole set of metabolic changes, both in the tumour and the surrounding tissues. Cancer and metabolism, and therefore diet, are inextricably linked. And, as discussed on this site in the past, there is evidence that altering diet can impact cancer treatments as in the work that looked at chemo response and fasting. There is another reason for looking at this book - the authors (Professor Tony Howell and Dr Michelle Harvie) are both working in breast cancer research, and are involved specifically in helping patients reduce their chances of getting the disease or reducing the risk of recurrence. One of the authors, Tony Howell, is well known to regular readers of this site for his work on the reverse Warburg effect and his association with Michael Lisanti and the development of new theories that link cancer with metabolism.
That said, this is primarily a book about diets and losing weight rather than a book specifically about cancer. Although the links to cancer are there in the text, and many of the patient stories include mention of cancer, the main aim is to help readers lose weight and keep it off. And, in doing so, to reap the overall health benefits across the board.
So, what is the 2-day Diet, and how does it differ from the thousands of other diet books on the market? A key point to make up front is that this is a diet that's been backed up by clinical data. There are no celebrity endorsements, no one selling expensive supplements or foods, no hand waving or bold claims unsupported by evidence. This is a diet that has been shown to work, it's that simple. Simple too is the basic idea behind the diet - it's simpler to stick to a strict diet for two days per week than it is for seven. And, importantly, the changes induced by a strict two day a week diet are significant enough to cause changes in body weight, glucose tolerance, mood and so on.
Wednesday, 6 March 2013
The 2-Day Diet
Wednesday, 27 February 2013
PDT Norfolk
The mainstays of cancer treatment remain chemotherapy, surgery and radiotherapy. These are the big three treatment modalities and have, largely, remained in place as the core weapons in the arsenal of oncologists despite the advent of a number of newer treatments. However, there is a class of treatments called ablative therapies that really need to become the fourth big weapon in the anti-cancer arsenal. Ablative therapies include photodynamic therapy (PDT), cryoablation, radio-frequency or microwave ablation and the new kid on the block, irreversible electroporation (which I have previously written about here).
Of these treatments, which all take the approach of directly and physically attacking tumours rather indirectly using drugs or radiation, it is PDT which is the most mature and most widely used. PDT works by injecting a light sensitive drug (called a photosensitiser) into a patient and then letting the drug accumulate in tumour cells – normal cells do not take up the drug to the same extent. Once the drug has been absorbed by the tumour light is applied to it – usually by a surgeon operating to gain access to the tumour and then shining a laser or LED directly on to the tumour. The photosensitive drug in the tumour cells reacts to the light and in the process kills the cell. In this way PDT can be used to destroy solid tumours directly.
While PDT is the most mature of the ablative treatments, it’s still not used widely enough in the UK, and even many oncologists remain unaware that it is available and that it’s a viable treatment option for their patients. This is a treatment that works, can be used against a wide variety of tumour types and does not produce the long-term side-effects of radiotherapy or chemotherapy. If ever there was a treatment that needed to become more widely known and available to more patients it’s this one. And, luckily, there are people around who are actively campaigning to raise awareness of PDT amongst the medical profession, amongst patients and the general public.
One such group is PDT Norfolk (take a visit to their site here: http://www.pdtnorfolk.co.uk/). Recently I travelled up from London to meet with the team at PDT Norfolk to discuss some of the science, some strategy and ways that we could work together. It was a good meeting and I think some very positive ideas came out of it. I think this is a campaign that has the potential to advance research in PDT as well as to raise the profile of the treatment, provide resources for patients and help to bring this treatment to a wider range of patients.
Of these treatments, which all take the approach of directly and physically attacking tumours rather indirectly using drugs or radiation, it is PDT which is the most mature and most widely used. PDT works by injecting a light sensitive drug (called a photosensitiser) into a patient and then letting the drug accumulate in tumour cells – normal cells do not take up the drug to the same extent. Once the drug has been absorbed by the tumour light is applied to it – usually by a surgeon operating to gain access to the tumour and then shining a laser or LED directly on to the tumour. The photosensitive drug in the tumour cells reacts to the light and in the process kills the cell. In this way PDT can be used to destroy solid tumours directly.
While PDT is the most mature of the ablative treatments, it’s still not used widely enough in the UK, and even many oncologists remain unaware that it is available and that it’s a viable treatment option for their patients. This is a treatment that works, can be used against a wide variety of tumour types and does not produce the long-term side-effects of radiotherapy or chemotherapy. If ever there was a treatment that needed to become more widely known and available to more patients it’s this one. And, luckily, there are people around who are actively campaigning to raise awareness of PDT amongst the medical profession, amongst patients and the general public.
One such group is PDT Norfolk (take a visit to their site here: http://www.pdtnorfolk.co.uk/). Recently I travelled up from London to meet with the team at PDT Norfolk to discuss some of the science, some strategy and ways that we could work together. It was a good meeting and I think some very positive ideas came out of it. I think this is a campaign that has the potential to advance research in PDT as well as to raise the profile of the treatment, provide resources for patients and help to bring this treatment to a wider range of patients.
Tuesday, 19 February 2013
Of Mice and Men
I’ve written about the state of cancer research on a number
of occasions in the past, in particular focusing on the use of different models
of cancer – for example here: http://www.anticancer.org.uk/2012/05/wrong-models-of-cancer-part-2.html
and here: http://www.anticancer.org.uk/2012/04/standards-in-cancer-research.html
and here: http://www.anticancer.org.uk/2011/11/test-tube-cancer-cells-and-people.html.
So I hope it’s not getting repetitive to raise the subject again in the light
of an important new paper in the Proceedings of the National Academy of
Sciences (PNAS). The paper, Genomic responses in mouse models poorly mimic human inflammatory diseases
is not about cancer as such, but it’s as important and relevant as any paper on
cancer.
The opening line of the paper makes plain why these results are important:
And it’s true enough in most areas of medicine, but none more so than in cancer research, where the mouse model is king. But the only problem is that mouse models don’t always match human disease profiles at all well. In the specific case that this paper outlines, it turns out that mouse models of massive inflammatory responses in critically ill patients are miles apart. To quote from the paper again:
The reason for this divergence turns out to be because the relationship between genes changed in human patients bears little relationship to the genes expressed in the mouse models of the diseases – the relationship is pretty much random. However, for years scientists who have been studying these diseases have focused on drugs that work for mice and then these drugs have subsequently failed in humans. Not only has this cost millions, it also means that much research effort has been wasted in targeting genes that have nothing to do with human diseases. It also means that potentially useful drugs have been abandoned precisely because they failed to do anything in mice.
And it’s not just inflammatory diseases at stake – the same is true in cancer research. We can only speculate on how much money, effort and intellectual energy has been wasted on research that doesn’t apply to people. The reliance on test tubes and mouse models means that much time and effort has been for nothing.
Something needs to change.
The opening line of the paper makes plain why these results are important:
A cornerstone of modern biomedical research is the use of mouse models to explore basic pathophysiological mechanisms, evaluate new therapeutic approaches, and make go or no-go decisions to carry new drug candidates forward into clinical trials.
And it’s true enough in most areas of medicine, but none more so than in cancer research, where the mouse model is king. But the only problem is that mouse models don’t always match human disease profiles at all well. In the specific case that this paper outlines, it turns out that mouse models of massive inflammatory responses in critically ill patients are miles apart. To quote from the paper again:
The success rate is even worse for those trials in the field of inflammation, a condition present in many human diseases. To date, there have been nearly 150 clinical trials testing candidate agents intended to block the inflammatory response in critically ill patients, and every one of these trials failed.
The reason for this divergence turns out to be because the relationship between genes changed in human patients bears little relationship to the genes expressed in the mouse models of the diseases – the relationship is pretty much random. However, for years scientists who have been studying these diseases have focused on drugs that work for mice and then these drugs have subsequently failed in humans. Not only has this cost millions, it also means that much research effort has been wasted in targeting genes that have nothing to do with human diseases. It also means that potentially useful drugs have been abandoned precisely because they failed to do anything in mice.
And it’s not just inflammatory diseases at stake – the same is true in cancer research. We can only speculate on how much money, effort and intellectual energy has been wasted on research that doesn’t apply to people. The reliance on test tubes and mouse models means that much time and effort has been for nothing.
Something needs to change.
Wednesday, 13 February 2013
LFS SIGNIFY Trial Looking for Volunteers
This just in from the people running the SIGNIFY trial for Li Fraumeni Syndrome:
We are conducting a small scale pilot study to investigate the use of whole body magnetic resonance imaging (MRI) in families with Li Fraumeni Syndrome.
We would like to enrol individuals in the trial who are between 18 and 60 years old and are known to have a genetic mutation (alteration) in the P53 gene as well as unrelated people who do not carry the gene mutation whose scan results can be used as controls.
All study participants will undergo a whole body MRI scan at the Royal Marsden Hospital, Sutton, Surrey.
If you are interested please contact SIGNIFY study coordinator Dr Emma Killick or another member of the SIGNIFY team at the Institute of Cancer Research on 0208 661 3375.
Tuesday, 29 January 2013
More On Stress and Cancer
A new open access research paper, 'Behavioural Stress Accelerates Prostate Cancer Development in Mice' (http://www.jci.org/articles/view/63324), adds more detail to the emerging picture of the relationship between stress and cancer. In this case the research team used mouse models to investigate the effect of stress on the development and progression of prostate cancer. And, as expected, those mice subjected to a stressful environment had greater incidence of cancer and higher rates of disease progression. And, just as importantly, some of the ill-effects of a stressful environment could be prevented through the use of drugs that interfere with the stress response to raised adrenalin and noradrenaline (i.e. like beta blockers).
From a science point of view this paper uncovers some of the molecular mechanisms at play here, which further advances our understanding of the relationship between psycho-social stresses, the resulting hormone stress response and the process of cancer initiation and progression.
However, it's the human angle that is of direct interest to me, (and to most readers of this article I would guess). What this new paper does is point out the horrible vicious circle that is at play here. As we know a cancer diagnosis is an incredibly frightening and stressful experience. It shakes your world up completely. The body responds to this stress by releasing adrenaline and other stress hormones. These can drive the cancer forward, causing even more stress as the disease progresses. It's not just the bad news. Cancer treatments are stressful too. Physically they are hard to take - there are side effects of drugs, radiotherapy and surgery. But there's also the stress induced by the whole process - the endless waiting, the delays, the uncertainty, the feeling of being disempowered.
From a science point of view this paper uncovers some of the molecular mechanisms at play here, which further advances our understanding of the relationship between psycho-social stresses, the resulting hormone stress response and the process of cancer initiation and progression.
However, it's the human angle that is of direct interest to me, (and to most readers of this article I would guess). What this new paper does is point out the horrible vicious circle that is at play here. As we know a cancer diagnosis is an incredibly frightening and stressful experience. It shakes your world up completely. The body responds to this stress by releasing adrenaline and other stress hormones. These can drive the cancer forward, causing even more stress as the disease progresses. It's not just the bad news. Cancer treatments are stressful too. Physically they are hard to take - there are side effects of drugs, radiotherapy and surgery. But there's also the stress induced by the whole process - the endless waiting, the delays, the uncertainty, the feeling of being disempowered.
Tuesday, 15 January 2013
Statement from Star Throwers
Dr Henry Mannings Restrictions Lifted After Review Hearing
Star Throwers are delighted to declare that all restrictions placed on Dr Henry Mannings imposed after an initial Interim Orders Panel (IOP) hearing on the 27th November 2012 have been revoked.
Back in November, an Interim Orders Panel imposed an order on Dr Mannings to restrict him from prescribing any medication.
At the IOP review hearing on Monday 14th January 2013, Dr Mannings, who represented himself, produced additional scientific evidence to the panel to prove the efficacy and safety of his approach in the cases of the two patients in question. He also reiterated the testimonials from eminent specialists which disagreed with and challenged the allegations made. Furthermore, the petition which has garnered approximately 3000 signatories so far was brought to the panel's attention, along with the hundreds of letters of support written from patients and families of patients.
In their conclusion, the Interim Orders Review Panel wrote: "The scientific papers to which the Panel has been referred indicate that the treatment which you gave was minimally toxic in the dosage you prescribed.
“In light of this additional information it does not consider that you present a risk to the public which makes it necessary to impose an interim order. It considers that an interim order could have a serious impact on you and the patients in your care and the risk posed does not justify these consequences.
“In all the circumstances, the Panel has determined that it is no longer necessary for the protection of members of the public, in the public interest or in your own interests for your registration to be subject to an order. The previous interim order is therefore revoked."
The hearing was held in public at the request of Dr Mannings in order to have full transparency, and was attended by members of the press and supporters of Dr Mannings.
Dr Mannings said after the hearing: "I am obviously very pleased with the common sense shown by the interim panel and their realisation of all the good work that is done at Star Throwers, based on all the evidence that was shown, including the petition and letters of support.
He continued: “We are exceptionally pleased that we will now be treating patients again, but can only hope that the time lost whereby they had not received any treatments will not have any long term consequences. "
The GMC will continue their investigations into the veracity of the allegations and a full hearing may still ensue. In the meantime, however, it is a very positive result for Dr Mannings and his patients.
Star Throwers manager Steven Ho said: “We are delighted at this common sense outcome as we can now go back to work giving the best service we possibly can to our patients and continue our important work looking after people affected by cancer.
“Once again, we would like to thank every single person who signed our petition, wrote a letter of support or helped to spread the word through their friends, families, and the media. We did it!”
Star Throwers are delighted to declare that all restrictions placed on Dr Henry Mannings imposed after an initial Interim Orders Panel (IOP) hearing on the 27th November 2012 have been revoked.
Back in November, an Interim Orders Panel imposed an order on Dr Mannings to restrict him from prescribing any medication.
At the IOP review hearing on Monday 14th January 2013, Dr Mannings, who represented himself, produced additional scientific evidence to the panel to prove the efficacy and safety of his approach in the cases of the two patients in question. He also reiterated the testimonials from eminent specialists which disagreed with and challenged the allegations made. Furthermore, the petition which has garnered approximately 3000 signatories so far was brought to the panel's attention, along with the hundreds of letters of support written from patients and families of patients.
In their conclusion, the Interim Orders Review Panel wrote: "The scientific papers to which the Panel has been referred indicate that the treatment which you gave was minimally toxic in the dosage you prescribed.
“In light of this additional information it does not consider that you present a risk to the public which makes it necessary to impose an interim order. It considers that an interim order could have a serious impact on you and the patients in your care and the risk posed does not justify these consequences.
“In all the circumstances, the Panel has determined that it is no longer necessary for the protection of members of the public, in the public interest or in your own interests for your registration to be subject to an order. The previous interim order is therefore revoked."
The hearing was held in public at the request of Dr Mannings in order to have full transparency, and was attended by members of the press and supporters of Dr Mannings.
Dr Mannings said after the hearing: "I am obviously very pleased with the common sense shown by the interim panel and their realisation of all the good work that is done at Star Throwers, based on all the evidence that was shown, including the petition and letters of support.
He continued: “We are exceptionally pleased that we will now be treating patients again, but can only hope that the time lost whereby they had not received any treatments will not have any long term consequences. "
The GMC will continue their investigations into the veracity of the allegations and a full hearing may still ensue. In the meantime, however, it is a very positive result for Dr Mannings and his patients.
Star Throwers manager Steven Ho said: “We are delighted at this common sense outcome as we can now go back to work giving the best service we possibly can to our patients and continue our important work looking after people affected by cancer.
“Once again, we would like to thank every single person who signed our petition, wrote a letter of support or helped to spread the word through their friends, families, and the media. We did it!”
Monday, 14 January 2013
Henry Mannings - Successful Appeal
It's with great pleasure that I can report that Dr Henry Manning's appeal to the GMC's Interim Orders Panel has been successful and that all restrictions have been lifted. This is great news as it means that Henry can pick up where he left off treating patients at Star Throwers.
While we all should all be pleased, I can't help but feel angry at the whole affair. Effectively treatment was interrupted for cancer patients with no other options. And, just as importantly it cast a cloud over Dr Mannings professional reputation - one that effected his ability to earn a living in the short term and which may have damaged his reputation permanently in the long term. And why? Because one other doctor took it upon himself to make a complaint that had no foundation. As anyone who reads the transcripts can see, this lone doctor pretended to speak on behalf of his colleagues when in fact he was speaking for no one but himself. Will there be any come back? I'm not holding my breath, but if this doctor had any integrity he'd make a public apology.
While we all should all be pleased, I can't help but feel angry at the whole affair. Effectively treatment was interrupted for cancer patients with no other options. And, just as importantly it cast a cloud over Dr Mannings professional reputation - one that effected his ability to earn a living in the short term and which may have damaged his reputation permanently in the long term. And why? Because one other doctor took it upon himself to make a complaint that had no foundation. As anyone who reads the transcripts can see, this lone doctor pretended to speak on behalf of his colleagues when in fact he was speaking for no one but himself. Will there be any come back? I'm not holding my breath, but if this doctor had any integrity he'd make a public apology.
Subscribe to:
Posts (Atom)